Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Tampere – page 5

276 clinical trials in Tampere, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Tampere at a glance
276
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

276 trials in Tampere

Open in trial search

Peripheral arterial occlusive disease

Recruiting

Study of APAC (antiplatelet, anticoagulant) treatment in patients with peripheral arterial disease and chronic limb-threatening ischemia during blood vessel restoration procedure

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Major depression

Recruiting

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Renal impairment

Recruiting

Study Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:University Of Helsinki

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Cough

Recruiting

Study on the Effectiveness of Fluticasone Propionate and Amoxicillin-Clavulanic Acid for Children with Long-Lasting Cough

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Pirkanmaan hyvinvointialue

Atrial fibrillation+2

Recruiting

Study on Early vs. Late Restart of Anticoagulation with Edoxaban, Apixaban, and Warfarin for Patients with Chronic Subdural Hematoma and Atrial Fibrillation

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-Yhtymae

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Ovarian cancer recurrent+1

Recruiting

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Tampere

What the registry says about research in the country

01 Infectious Disease Prevention

Extensive research focusing on vaccine development against multiple viral infections, including influenza, RSV, and meningococcal disease. Clinical trials are evaluating novel immunization strategies for different age groups.

  • Influenza vaccine trials for adults 60+
  • RSV prevention in infants and elderly
  • Meningococcal vaccines for children

Multiple studies are investigating immune responses and long-term protection against respiratory infections.

02 Oncology Research

Innovative trials exploring new treatments for various cancers, with emphasis on advanced solid tumors and blood cancers. Studies combine novel therapeutic approaches with existing treatments.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Focus on developing targeted therapies and improving treatment outcomes for cancer patients.

03 Diagnostic Medicine

Research evaluating advanced diagnostic techniques, particularly in emergency medicine and acute conditions. Studies compare different imaging methods and their effectiveness.

  • CT scanning protocols
  • Emergency diagnostics
  • Treatment response monitoring

Emphasis on improving diagnostic accuracy while considering patient safety.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.